Personalizing health care: Feasibility and future implications

Brian Godman, Alexander Finlayson, Parneet Cheema, Eva Zebedin-Brandl, Iñaki Gutiérrez-Ibarluzea, Jan Jones, Rickard Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrairo, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan Haycox & 25 others Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven-Åke Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno Van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali, Lars Gustafsson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients
Original languageEnglish
Article number179
Pages (from-to)1-23
Number of pages23
JournalBMC Medicine
Volume11
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Precision Medicine
Delivery of Health Care
Costs and Cost Analysis
Pharmacogenetics
Patient Care
Biomarkers
Phenotype
Drug Therapy
Therapeutics
Pharmaceutical Preparations

Cite this

Godman, B., Finlayson, A., Cheema, P., Zebedin-Brandl, E., Gutiérrez-Ibarluzea, I., Jones, J., ... Gustafsson, L. (2013). Personalizing health care: Feasibility and future implications. BMC Medicine, 11, 1-23. [179]. https://doi.org/10.1186/1741-7015-11-179
Godman, Brian ; Finlayson, Alexander ; Cheema, Parneet ; Zebedin-Brandl, Eva ; Gutiérrez-Ibarluzea, Iñaki ; Jones, Jan ; Malmström, Rickard ; Asola, Elina ; Baumgärtel, Christoph ; Bennie, Marion ; Bishop, Iain ; Bucsics, Anna ; Campbell, Stephen ; Diogene, Eduardo ; Ferrairo, Alessandra ; Fürst, Jurij ; Garuoliene, Kristina ; Gomes, Miguel ; Harris, Katharine ; Haycox, Alan ; Herholz, Harald ; Hviding, Krystyna ; Jan, Saira ; Kalaba, Marija ; Kvalheim, Christina ; Laius, Ott ; Lööv, Sven-Åke ; Malinowska, Kamila ; Martin, Andrew ; McCullagh, Laura ; Nilsson, Fredrik ; Paterson, Ken ; Schwabe, Ulrich ; Selke, Gisbert ; Sermet, Catherine ; Simoens, Steven ; Tomek, Dominik ; Vlahovic-Palcevski, Vera ; Voncina, Luka ; Wladysiuk, Magdalena ; Van Woerkom, Menno ; Wong-Rieger, Durhane ; Zara, Corrine ; Ali, Raghib ; Gustafsson, Lars. / Personalizing health care: Feasibility and future implications. In: BMC Medicine. 2013 ; Vol. 11. pp. 1-23.
@article{7943026ece054b7d914bb8ce1a43e8f3,
title = "Personalizing health care: Feasibility and future implications",
abstract = "Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients",
author = "Brian Godman and Alexander Finlayson and Parneet Cheema and Eva Zebedin-Brandl and I{\~n}aki Guti{\'e}rrez-Ibarluzea and Jan Jones and Rickard Malmstr{\"o}m and Elina Asola and Christoph Baumg{\"a}rtel and Marion Bennie and Iain Bishop and Anna Bucsics and Stephen Campbell and Eduardo Diogene and Alessandra Ferrairo and Jurij F{\"u}rst and Kristina Garuoliene and Miguel Gomes and Katharine Harris and Alan Haycox and Harald Herholz and Krystyna Hviding and Saira Jan and Marija Kalaba and Christina Kvalheim and Ott Laius and Sven-{\AA}ke L{\"o}{\"o}v and Kamila Malinowska and Andrew Martin and Laura McCullagh and Fredrik Nilsson and Ken Paterson and Ulrich Schwabe and Gisbert Selke and Catherine Sermet and Steven Simoens and Dominik Tomek and Vera Vlahovic-Palcevski and Luka Voncina and Magdalena Wladysiuk and {Van Woerkom}, Menno and Durhane Wong-Rieger and Corrine Zara and Raghib Ali and Lars Gustafsson",
year = "2013",
doi = "10.1186/1741-7015-11-179",
language = "English",
volume = "11",
pages = "1--23",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",

}

Godman, B, Finlayson, A, Cheema, P, Zebedin-Brandl, E, Gutiérrez-Ibarluzea, I, Jones, J, Malmström, R, Asola, E, Baumgärtel, C, Bennie, M, Bishop, I, Bucsics, A, Campbell, S, Diogene, E, Ferrairo, A, Fürst, J, Garuoliene, K, Gomes, M, Harris, K, Haycox, A, Herholz, H, Hviding, K, Jan, S, Kalaba, M, Kvalheim, C, Laius, O, Lööv, S-Å, Malinowska, K, Martin, A, McCullagh, L, Nilsson, F, Paterson, K, Schwabe, U, Selke, G, Sermet, C, Simoens, S, Tomek, D, Vlahovic-Palcevski, V, Voncina, L, Wladysiuk, M, Van Woerkom, M, Wong-Rieger, D, Zara, C, Ali, R & Gustafsson, L 2013, 'Personalizing health care: Feasibility and future implications', BMC Medicine, vol. 11, 179, pp. 1-23. https://doi.org/10.1186/1741-7015-11-179

Personalizing health care: Feasibility and future implications. / Godman, Brian; Finlayson, Alexander; Cheema, Parneet; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Iñaki; Jones, Jan; Malmström, Rickard; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrairo, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel ; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven-Åke; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik ; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; Van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars.

In: BMC Medicine, Vol. 11, 179, 2013, p. 1-23.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Personalizing health care: Feasibility and future implications

AU - Godman, Brian

AU - Finlayson, Alexander

AU - Cheema, Parneet

AU - Zebedin-Brandl, Eva

AU - Gutiérrez-Ibarluzea, Iñaki

AU - Jones, Jan

AU - Malmström, Rickard

AU - Asola, Elina

AU - Baumgärtel, Christoph

AU - Bennie, Marion

AU - Bishop, Iain

AU - Bucsics, Anna

AU - Campbell, Stephen

AU - Diogene, Eduardo

AU - Ferrairo, Alessandra

AU - Fürst, Jurij

AU - Garuoliene, Kristina

AU - Gomes, Miguel

AU - Harris, Katharine

AU - Haycox, Alan

AU - Herholz, Harald

AU - Hviding, Krystyna

AU - Jan, Saira

AU - Kalaba, Marija

AU - Kvalheim, Christina

AU - Laius, Ott

AU - Lööv, Sven-Åke

AU - Malinowska, Kamila

AU - Martin, Andrew

AU - McCullagh, Laura

AU - Nilsson, Fredrik

AU - Paterson, Ken

AU - Schwabe, Ulrich

AU - Selke, Gisbert

AU - Sermet, Catherine

AU - Simoens, Steven

AU - Tomek, Dominik

AU - Vlahovic-Palcevski, Vera

AU - Voncina, Luka

AU - Wladysiuk, Magdalena

AU - Van Woerkom, Menno

AU - Wong-Rieger, Durhane

AU - Zara, Corrine

AU - Ali, Raghib

AU - Gustafsson, Lars

PY - 2013

Y1 - 2013

N2 - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients

AB - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients

U2 - 10.1186/1741-7015-11-179

DO - 10.1186/1741-7015-11-179

M3 - Article

VL - 11

SP - 1

EP - 23

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

M1 - 179

ER -

Godman B, Finlayson A, Cheema P, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J et al. Personalizing health care: Feasibility and future implications. BMC Medicine. 2013;11:1-23. 179. https://doi.org/10.1186/1741-7015-11-179